RIO

Rio Tinto reported Q3 2026 results with Pilbara iron ore shipments rising 2% year-over-year to 85.7 Mt, while production declined 1%. Copper production remained flat at 205 thousand tons, with weakness at Kennecott and Escondida offset by a 27% surge at Oyu Tolgoi. The company maintained its 2026 guidance for copper output (800-870 kt) and Pilbara shipments (323-338 Mt), while projecting lower unit costs across both segments.

Fieldstone Bio, a synthetic biology company, has been selected for the Mining Tech Accelerator program run by Founders Factory in partnership with Rio Tinto. The company's platform combines synthetic biology, hyperspectral imaging, and data analysis to provide rapid elemental measurements for ore body characterization during exploration and mining operations, addressing the critical knowledge gap in mining decision-making.

Albemarle (ALB) and Rio Tinto (RIO) are both well-positioned to benefit from growing lithium demand driven by electric vehicles and energy storage. ALB is executing capacity expansion projects and achieving significant cost savings, while RIO is advancing major lithium projects with a stronger balance sheet. Rio Tinto appears to offer better value with more attractive valuation metrics, higher return on equity, and rising earnings estimates, making it the more favorable investment option currently.